Diffuse Large B-Cell and Follicular Lymphoma Specialty Channel

Diffuse Large B-Cell and Follicular Lymphoma

Specialty Channel

News

Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL

01/16/2025

Emily Estrada ;

Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.

Inferior survival outcomes are...

01/16/2025

Oncology

Conference Coverage

Time of CAR-T Cell Therapy Failure May Predict Outcomes of Bispecific Antibody Therapy Among Patients With Relapsed or Refractory Large B-Cell Lymphoma

12/05/2024

Allison Casey ;

According to a retrospective, real-world study presented at the 2024 ASH Annual Meeting & Exposition, the timing of CAR-T cell therapy failure may predict the outcomes for bispecific antibody therapies for patients with relapsed/refractory...

According to a retrospective,...

12/05/2024

Oncology

Conference Coverage

CD22-Directed CAR-T Therapy Provides Durable Remission and Long-Term Survival in Large B-Cell Lymphoma

12/05/2024

Among patients with large B-cell lymphoma progressing after CD19-directed CAR T-cell therapy, treatment with CD22-Directed CAR T-cells provided durable remissions and long-term survival after 3 years, according to follow-up data presented at...

Among patients with large B-cell...

12/05/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

Videos

Evaluating the Efficacy of R-Mini-CHOP With or Without Oral Azacytidine for Elderly Patients With DLBCL

07/29/2024

Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...

Elizabeth Brem, MD, shares...

07/29/2024

Oncology

Videos

CAR T-Cell Therapy vs Other Novel Therapies for Elderly Patients With Relapsed DLBCL

07/29/2024

At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.

At the 2024 Great Debates &...

07/29/2024

Oncology

Julie Vose, MD, University of Nebraska Medical Center

Videos

Optimizing Epcoritamab Therapy to Reduce CRS and ICANS Among Patients With R/R Follicular Lymphoma

07/09/2024

Julie Vose, MD, presents data from an optimization cohort that demonstrated improved safety of optimized epcoritamab treatment to strategically reduce CRS and ICANS among patients with R/R follicular lymphoma in the outpatient setting.

Julie Vose, MD, presents data...

07/09/2024

Oncology

Videos

Updates in the Evolving Diffuse Large B-Cell Lymphoma Treatment Landscape

06/27/2024

Matthew Matasar, MD, shares expert insights into the current and evolving “potentially practice-changing” clinical trial research landscape for the treatment of patients with diffuse large B-cell lymphoma.

Matthew Matasar, MD, shares...

06/27/2024

Oncology

FDA Approval

FDA Approves Epcoritamab for Relapsed/Refractory Follicular Lymphoma

06/26/2024

The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adult patients with relapsed or refractory follicular lymphoma who received ≥2 prior lines of therapy.

The FDA granted accelerated...

06/26/2024

Oncology

Quiz

Lisocabtagene Maraleucel Approved for Patients With R/R FL

06/05/2024

True or False: The FDA’s accelerated approval of lisocabtagene maraleucel for patients with R/R follicular lymphoma was based on results from a primary efficacy population of 94 patients with PET-positive disease at baseline or following...

True or False: The FDA’s...

06/05/2024

Oncology

Conference Coverage

R-CHOP Plus Venetoclax Fails to Improve PFS Among Patients With DLBCL With Double Expressor Lymphoma

05/29/2024

Amber Denham

Venetoclax added to R-CHOP among patients with DLBCL with expression of MYC and BCL2 did not improve progression-free survival, and caused higher toxicity, according to a phase 2 study presented at the 2024 ASCO Annual Meeting.

Venetoclax added to R-CHOP among...

05/29/2024

Oncology

News

Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL

01/16/2025

Emily Estrada ;

Inferior survival outcomes are...

01/16/2025

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that...

08/07/2024

Oncology

FDA Approval

FDA Approves Epcoritamab for Relapsed/Refractory Follicular Lymphoma

06/26/2024

The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adult patients with relapsed or refractory follicular lymphoma who received ≥2 prior lines of therapy.

The FDA granted accelerated...

06/26/2024

Oncology

FDA Approval

FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma

05/16/2024

Amber Denham

The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.

The US Food and Drug...

05/16/2024

Oncology

News

Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma

05/08/2024

Amber Denham

According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...

According to a retrospective...

05/08/2024

Oncology

News

IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization

04/19/2024

Amber Denham

According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...

According to phase 2 results,...

04/19/2024

Oncology

News

Short Induction Therapy Followed by High-Dose Chemotherapy and Autologous HSCT Demonstrates Activity for Older Patients With Primary Diffuse Large B-Cell CNS Lymphoma

04/09/2024

Amber Denham

According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.

According to phase 2 data, short...

04/09/2024

Oncology

FDA Approval

FDA Approves Zanubrutinib for Patients With Relapsed/Refractory Follicular Lymphoma

03/11/2024

Amber Denham

The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.

The FDA granted accelerated...

03/11/2024

Oncology

News

Polatuzumab Vedotin Plus Rituximab and Lenalidomide Efficacy Among Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

02/21/2024

Amber Denham ;

Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.

Polatuzumab vedotin with...

02/21/2024

Oncology

News

Blinatumomab Consolidation After Auto-SCT Yields Safety, Tolerability Among Patients With Relapsed DLBCL

02/02/2024

Amber Denham ;

Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.

Blinatumomab consolidation after...

02/02/2024

Oncology

News

Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer

01/17/2025

Allison Casey ;

The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...

The US Food and Drug...

01/17/2025

Oncology

FDA Alerts

Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer

01/17/2025

Stephanie Holland ;

Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.

Based on results from the phase...

01/17/2025

Oncology

FDA Approval

FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL

01/17/2025

Gina Tomaine ;

The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.

The FDA granted approval to...

01/17/2025

Oncology

News

Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL

01/16/2025

Emily Estrada ;

Inferior survival outcomes are...

01/16/2025

Oncology

News

Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population

01/15/2025

Emily Estrada ;

Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.

Treatment with ciltacabtagene...

01/15/2025

Oncology

News

Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer

01/14/2025

Stephanie Holland ;

According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.

According to results from the...

01/14/2025

Oncology

News

First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer

01/14/2025

Stephanie Holland ;

According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.

According to results from the...

01/14/2025

Oncology

News

Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma

01/08/2025

Stephanie Holland ;

Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.

Final results from the phase 3...

01/08/2025

Oncology

News

Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

01/08/2025

Stephanie Holland ;

According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.

According to results from the...

01/08/2025

Oncology

News

Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

01/06/2025

Stephanie Holland ;

Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...

Interim analysis results from...

01/06/2025

Oncology

Interactive Features

Quiz

Lisocabtagene Maraleucel Approved for Patients With R/R FL

06/05/2024

True or False: The FDA’s...

06/05/2024

Oncology

Quiz

Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL

04/11/2024

Oncology

Quiz

Chemo-Free Mosunetuzumab Monotherapy for 3 L+ Follicular Lymphoma

03/27/2024

True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...

True or False: According to...

03/27/2024

Oncology

Quiz

Treating Follicular Lymphoma With Obinutuzumab Immunochemotherapy Versus Rituximab Immunochemotherapy

02/05/2024

What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?

What was the key finding from...

02/05/2024

Oncology

Quiz

Zanubrutinib Plus Obinutuzumab vs Obinutuzumab Alone for R/R FL

01/29/2024

True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...

True or False: Findings from the...

01/29/2024

Oncology

Quiz

Lenvatinib Plus Pembrolizumab for Patients With Advanced or Recurrent Endometrial Cancer

12/20/2024

Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!

Do you know if first-line...

12/20/2024

Oncology

Quiz

For your patients with MF and anemia, which of the following would preclude you from initiating ruxolitinib at diagnosis?

12/13/2024

Oncology

Quiz

You just diagnosed your patient with intermediate-1 primary MF. The patient has a spleen that is palpable 5 cm below the LCM; has mild disease-related symptoms; and is not anemic. What would you typically do next for a patient like this?

12/13/2024

Oncology

Quiz

What is your primary treatment goal when treating your patients with MF?

12/13/2024

Oncology

Quiz

At what baseline spleen size do you typically consider initiating treatment for a patient with MF who presents with mild to moderate symptoms?

12/13/2024

Oncology

Quiz

While a target Hct level for patients with PV may be <45%, what is the maximum Hct level you would allow before changing your management approach?

12/12/2024

Oncology

Quiz

Your PV patient is on their maximum tolerated dose of HU. At this point, what is the maximum Hct level you would allow before changing your management approach?

12/12/2024

Oncology

Quiz

Managing for the risk of thrombosis is a key treatment goal for patients with PV. When it comes to managing for the risk of thrombosis, which counts are you most concerned about?

12/12/2024

Oncology

Quiz

When it comes to managing for the risk of thrombosis, what is the maximum WBC count you would allow for your patients with PV?

12/12/2024

When it comes to managing for the risk of thrombosis, what is the maximum WBC count you would allow for your patients with PV?

When it comes to managing for...

12/12/2024

Oncology

Quiz

Adjuvant Chemotherapy Plus Radiation for Patients With High-Risk Endometrial Cancer

11/26/2024

Do you know what the 5-year progression-free survival rate among patients with high-risk endometrial cancer was when treated with adjuvant chemotherapy with docetaxel and cisplatin followed by pelvic radiation therapy?

Do you know what the 5-year...

11/26/2024

Oncology